TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) will likely be issuing its quarterly earnings data before the market ...

Thermo Fisher Scientific (TMO) offers growth potential with diverse revenue streams, fair valuation, and strong CAGR ...

Investors focused on top-and-bottom-line performance—important as they are—do so at the risk of neglecting another crucial ...

Lyndra secured $101m in Series E financing to advance its pipeline of long-lasting oral therapy products. "Lyndra and Thermo ...

We came across a bullish thesis on Thermo Fisher Scientific Inc. (TMO) on Rijnberk InvestInsights’ Substack by Daan Rijnberk.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific (NYSE:TMO – Free Report) from a market perform rating to an ...

The LYNX technology originated in the Traverso and Langer Laboratories at MIT, with which Lyndra has an exclusive technology ...

As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is ...

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...